© 1976

Atherosclerosis Drug Discovery

  • Charles E. Day

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 67)

Table of contents

  1. Front Matter
    Pages i-x
  2. Primate Models

  3. Rabbit Models

    1. Front Matter
      Pages 121-121
    2. David Kritchevsky, Shirley A. Tepper, Jon A. Story
      Pages 143-147
    3. Y. S. Kwak, K. T. Lee, D. N. Kim
      Pages 149-167
    4. Joseph D. Pool, John L. Gainer, Guy M. Chisolm III
      Pages 205-211
  4. Rodent Models

    1. Front Matter
      Pages 213-213
    2. Paul E. Schurr, John R. Schultz, Charles E. Day
      Pages 215-229
    3. Charles E. Day, Paul E. Schurr, William E. Heyd, Daniel Lednicer
      Pages 231-249
    4. W. A. Phillips, J. M. Ratchford, J. R. Schultz
      Pages 251-265
    5. Nozomu Takeuchi, Masami Ito, Yuichi Yamamura
      Pages 267-288

About this book


Although atherosclerosis is the leading cause of death in the so-called affluent societies, there is presently no drug in our pharmacologic armamentarium against disease to either prevent or reverse this insidious killer and debilitant of human lives. Because of this void the First Brook Lodge Symposium on Anti­ Atherosclerosis Drug Discovery was convened at Brook Lodge in Augusta, Michigan, August 13-15, 1975. The symposium was sponsored by The Upjohn Company and was international in scope, with investi­ gators attending from such countries as England, Japan, Belgium, and Italy. The symposium focused on the problems associated with the discovery and evaluation of new drugs effective in preventing or reversing atherosclerosis. The thrust of material is centered around animal models useful as tools in the search and evaluation of new drugs. Broadly categorized, the models are nonhuman primates, rabbits, rodents, quail, and tissue culture. The material is a mix of studies on serum lipids and, more importantly, of studies on the artery, irrespective of serum lipid levels. The prevention of arterial lesions, not reduction of serum lipids, is emphasized. A review of all anti-atherosclerotic agents, with the exception of hypolipidemic agents, is included in this volume of the proceedings of the symposium.


Lipoprotein artery atherosclerosis death drug drug discovery drugs evaluation lipide pharmacology prevention tissue

Editors and affiliations

  • Charles E. Day
    • 1
  1. 1.Atherosclerosis ResearchThe Upjohn CompanyKalamazooUSA

Bibliographic information

  • Book Title Atherosclerosis Drug Discovery
  • Editors Charles Day
  • Series Title Advances in Experimental Medicine and Biology
  • DOI
  • Copyright Information Springer-Verlag US 1976
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-306-39067-8
  • Softcover ISBN 978-1-4757-9309-3
  • eBook ISBN 978-1-4614-4618-7
  • Series ISSN 0065-2598
  • Edition Number 1
  • Number of Pages X, 467
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Cardiology
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology